Cardlytics, a financial data and marketing analytics startup, raises $70.2M in IPO, valued at ~$250M, closes 2.9% above $13 IPO price on first day of trading
Max A. Cherney / MarketWatch :
Context & Ripple Effects
Cardlytics' listing lands in a small but growing lane: enterprise data-analytics companies testing the public markets. Alteryx's 2017 IPO had already shown the category could list successfully, closing up 10.7% on debut after raising $126M.
What makes Cardlytics notable is how little was left on the table: a 2.9% first-day gain is far below the pops that followed for peers like Medallia's 76% debut and Health Catalyst's 51% close — evidence its bankers priced the deal close to what the market would actually pay.
First-order effects
- Cardlytics converts private holdings into public stock, banking $70.2M at a ~$250M valuation while early investors get liquidity at a price that held up on day one rather than being repriced upward by a pop.
Second-order effects
- The muted debut against later outsized pops like Medallia's gives underwriters of subsequent data-analytics offerings a pricing benchmark — deals priced near fair value versus deals that leave double-digit gains for new buyers.
Third-order effects
- If transaction-data monetization keeps clearing both public listings and large private rounds — YipitData later raised up to $475M at a $1B+ valuation from Carlyle — the valuation gap between private data firms and freshly public ones narrows, weakening the IPO-as-pop-upside dynamic.
The trend: Data and analytics companies are steadily moving from private fundraising to public listings, with first-day pops shrinking where bankers price deals at true market value.